Trade Regeneron Pharmaceuticals, Inc. (Extended hours) - REGN CFD
Add to favourite- Summary
- Historical Data
| Spread | 7.19 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 740.05 |
| Open | 737.65 |
| 1-Year Change | -14.23% |
| Day's Range | 737.65 - 747.04 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 18, 2024 | 737.65 | -0.40 | -0.05% | 738.05 | 739.72 | 737.65 |
| Dec 17, 2024 | 739.71 | 19.76 | 2.74% | 719.95 | 744.33 | 714.95 |
| Dec 16, 2024 | 720.95 | -8.00 | -1.10% | 728.95 | 738.95 | 720.95 |
| Dec 13, 2024 | 731.54 | -6.41 | -0.87% | 737.95 | 740.70 | 727.02 |
| Dec 12, 2024 | 737.95 | -32.02 | -4.16% | 769.97 | 776.95 | 737.95 |
| Dec 11, 2024 | 760.95 | -12.00 | -1.55% | 772.95 | 780.93 | 760.95 |
| Dec 10, 2024 | 773.83 | -7.85 | -1.00% | 781.68 | 789.60 | 760.89 |
| Dec 9, 2024 | 780.16 | 4.21 | 0.54% | 775.95 | 799.90 | 769.35 |
| Dec 6, 2024 | 773.56 | 6.51 | 0.85% | 767.05 | 777.34 | 762.90 |
| Dec 5, 2024 | 764.36 | 18.25 | 2.45% | 746.11 | 767.63 | 745.10 |
| Dec 4, 2024 | 751.67 | 8.19 | 1.10% | 743.48 | 755.99 | 742.26 |
| Dec 3, 2024 | 748.02 | -11.00 | -1.45% | 759.02 | 764.35 | 746.34 |
| Dec 2, 2024 | 762.43 | 15.48 | 2.07% | 746.95 | 763.61 | 746.95 |
| Nov 29, 2024 | 744.95 | -3.42 | -0.46% | 748.37 | 753.85 | 738.00 |
| Nov 27, 2024 | 752.74 | 2.78 | 0.37% | 749.96 | 761.95 | 745.63 |
| Nov 26, 2024 | 750.07 | 7.48 | 1.01% | 742.59 | 753.74 | 733.11 |
| Nov 25, 2024 | 746.39 | 1.44 | 0.19% | 744.95 | 757.29 | 741.25 |
| Nov 22, 2024 | 735.86 | -6.19 | -0.83% | 742.05 | 751.02 | 735.86 |
| Nov 21, 2024 | 742.10 | -0.85 | -0.11% | 742.95 | 756.64 | 734.06 |
| Nov 20, 2024 | 740.28 | -0.34 | -0.05% | 740.62 | 749.79 | 732.01 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Regeneron Company profile
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.| Industry: | Bio Therapeutic Drugs |
777 Old Saw Mill River Road
TARRYTOWN
NEW YORK 10591
US
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com